Skip to content
10-Q

Quarterly Report

Raphael Pharmaceutical Inc. RAPH

0001213900-24-067723

← back to feed
Filed
Aug 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 12, 2024 18.7M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $120K
Cash And Equivalents Q2 2024 · Dec 31, 2023 $230K
Current Liabilities Q2 2024 · Jun 30, 2024 $418K
Current Liabilities Q2 2024 · Dec 31, 2023 $72K
Current Assets Q2 2024 · Jun 30, 2024 $126K
Current Assets Q2 2024 · Dec 31, 2023 $337K
Total Assets Q2 2024 · Jun 30, 2024 $128K
Total Assets Q2 2024 · Dec 31, 2023 $339K
Stock Issued Q2 2024 · May 31, 2024 40K sh
Shares Diluted Q2 2024 · Jun 30, 2023 16.11M sh
Shares Diluted Q2 2024 · Jun 30, 2023 16.04M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$614K
Stockholders Equity Q2 2024 · Jun 30, 2023 −$61K
Stockholders Equity Q2 2024 · Mar 31, 2023 −$9K
Stockholders Equity Q2 2024 · Dec 31, 2022 $106K
Eps Diluted Q2 2024 · Jun 30, 2023 $0.03
Eps Diluted Q2 2024 · Jun 30, 2023 $0.04
Eps Basic Q2 2024 · Jun 30, 2023 $0.03
Eps Basic Q2 2024 · Jun 30, 2023 $0.04
Sga Expense Q2 2024 · Jun 30, 2023 $126K
Sga Expense Q2 2024 · Jun 30, 2023 $270K
Rd Expense Q2 2024 · Jun 30, 2023 $293K
Rd Expense Q2 2024 · Jun 30, 2023 $407K
Net Income Q2 2024 · Jun 30, 2023 −$417K
Net Income Q2 2024 · Jun 30, 2023 −$681K
Net Income Q2 2024 · Mar 31, 2023 −$264K
Operating Income Q2 2024 · Jun 30, 2023 −$419K
Operating Income Q2 2024 · Jun 30, 2023 −$677K